Table 4.

Cytokine and immune modulatory molecule upregulation in mouse myeloma TEM following RV and BTZ combination treatment

SampleIFN-β, no. + MNC/×200 (SD)IFN-γ, no. + MNC/×200 (SD)MHC1, no. + MNC/×200 (SD)TAP1, no. + MNC/×200 (SD)TLR3, no. + MNC/×200 (SD)NF-κB, no. + MNC/×200 (SD)
Tumor-free control spleen0012.3 (4.4)2.0 (0.7)01.1 (0.4)
Vehicle control myeloma spleen7.1* (1.3)15.2 (5.5)19.5 (4.0)4.1 (1.1)13.5 (2.3)12.2 (3.3)
DV myeloma spleen4.9 (2.0)11.9 (5.9)27.4 (7.9)12.2 (4.7)20.1 (6.3)32.9 (6.0)
BTZ myeloma spleen15.0 (6.6)23.2 (8.2)29.0 (7.7)5.0 (2.8)34.3 (7.7)33.9 (5.7)
DV + BTZ myeloma spleen18.1 (5.8)28.9 (9.0)25.2 (8.2)15.9 (3.3)27.9 (9.2)28.9 (7.1)
LV myeloma spleen (low productive infection)14.1 (4.9)18.8 (4.3)111.9 (9.7)48.9 (7.7)109.4 (9.2)69.5 (5.9)
LV + BTZ myeloma spleen (productive infection)83.2 (8.95)76.1 (7.9)218.15 (17.1)91.3 (9.65)116.0 (9.25)76.35 (7.1)
  • SD, standard deviation; MNC, mononuclear cell.

  • * All cell counts were done at the interface of myeloma cells and normal spleen and represent the number of positive cells at ×200. N = 2, mean of 10 fields (SD).